Supriya Lifescience Ltd. reported a sharp 30.8% year-on-year rise in consolidated revenue for the first quarter of FY27, even as lower margins weighed on EBITDA and profit.
Revenue rose to Rs. 189.75 crore in Q1 FY27 from Rs. 145.07 crore in the year-ago quarter, according to the company’s unaudited financial results.
However, EBITDA fell to Rs. 47.46 crore, compared with Rs. 51.70 crore in Q1 FY26. The EBITDA margin consequently narrowed to 25.0% from 35.6%.
Profit after tax declined to Rs. 24.04 crore from Rs. 34.79 crore, while PAT margin dropped to 12.7% from 24.0%. Quarterly EPS stood at Rs. 2.99, against Rs. 4.32 a year earlier.
The company, a cGMP-compliant API manufacturer with a presence across more than 120 countries, said its growth during the quarter was supported by a diversified product portfolio and expanding international markets.
The Anesthetic segment remained the company’s largest therapeutic contributor, accounting for 48% of revenue in Q1 FY27, although its share declined from 53% in the year-ago quarter. Vitamins increased their contribution to 17% from 11%.
Geographically, Asia emerged as the largest market, contributing 39% of revenue, up from 32% in Q1 FY26. Europe accounted for 35%, LATAM for 20%, while North America and other markets contributed 3% each.
Exports remained a major growth driver, accounting for 81% of Q1 FY27 revenue, underscoring the company’s continued focus on international markets.
Supriya Lifescience said its product pipeline continued to gain momentum during the quarter. Its cardiovascular product, launched in Q3 FY26, began contributing revenue in Q4 FY26 and is expected to scale further.
The company also reported strong demand for its ADHD product in LATAM and Europe, with the product now being scaled up. Its Liquid Anesthetic product has been commercialised, with steady monthly supplies underway.
For FY27, the company plans approximately two launches each in Anesthetic and ADHD, as it looks to deepen its portfolio and create additional growth opportunities.
Capacity utilisation stood at 70% in Q1 FY27, compared with 74% in FY26 and 70% in FY25. The company currently has total reactor capacity of 932 KLPD across its manufacturing blocks.
At its Ambernath facility, finished dosage manufacturing capabilities have been commissioned across tablets, capsules, liquids, nasal, inhalation and injection dosage forms. Validation and registration batches are underway for dossier submissions.
The company is also expanding its research capabilities, with more than 68 scientists focused primarily on API and formulation process development. Two R&D centres have commenced operations at Ambernath and Lote, with the company targeting the addition of 3–4 products annually.
Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience Ltd., said, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets.
"Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth.”
